Berzosertib

Berzosertib is an investigational small-molecule drug that selectively inhibits the ATR kinase, a key protein in the DNA damage response pathway. Clinical trials have evaluated its potential, often in combination with chemotherapy or other targeted agents, for treating various advanced solid tumors including ovarian neoplasms, non-small cell lung cancer, and head and neck cancers.